Technical Analysis for ENTA - Enanta Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 13.51 -4.93% -0.70
ENTA closed down 4.93 percent on Monday, March 18, 2024, on 63 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Fell Below 200 DMA Bearish 0.00%
Stochastic Reached Oversold Weakness 0.00%
Outside Day Range Expansion 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -4.93%
Crossed Above 200 DMA Bullish -4.93%
Fell Below 20 DMA Bearish -2.53%
Fell Below 200 DMA Bearish -2.53%

   Recent Intraday Alerts

Alert Time
Down 5% about 12 hours ago
Rose Above Previous Day's High about 12 hours ago
20 DMA Resistance about 12 hours ago
Outside Day about 12 hours ago
Up 1% about 12 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Enanta Pharmaceuticals, Inc. Description

Enanta Pharmaceuticals, Inc., a biotechnology company, engages in the development of small molecule drugs for the infectious disease areas. Its product candidates include ABT-450, an inhibitor of NS3 protease that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV) infection; EDP-239, an NS5A Inhibitor for HCV infection; EDP-546, a Cyclophilin inhibitor, which is in preclinical studies for HCV infection treatment; and Nucleotide Polymerase inhibitor for HCV infection. The company also develops EDP-788, an intravenous drug for the treatment of methicillin-resistant Staphylococcus aureus bacteria. It has collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc. and Abbott Laboratories. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Infectious Diseases Chemical Compounds Infection Medical Research Viruses Hepatitis C Hepatitis C Virus HCV Staphylococcus Aureus Treatment Of Hepatitis Cyclophilin Cyclopropanes Methicillin HCV Infection Pyrrolidines

Is ENTA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 43.055
52 Week Low 8.08
Average Volume 246,548
200-Day Moving Average 13.93
50-Day Moving Average 13.06
20-Day Moving Average 14.35
10-Day Moving Average 14.75
Average True Range 0.75
RSI (14) 45.65
ADX 22.71
+DI 18.04
-DI 22.64
Chandelier Exit (Long, 3 ATRs) 13.99
Chandelier Exit (Short, 3 ATRs) 14.51
Upper Bollinger Bands 16.25
Lower Bollinger Band 12.45
Percent B (%b) 0.28
BandWidth 26.53
MACD Line 0.40
MACD Signal Line 0.64
MACD Histogram -0.2424
Fundamentals Value
Market Cap 285.82 Million
Num Shares 21.2 Million
EPS -6.57
Price-to-Earnings (P/E) Ratio -2.06
Price-to-Sales 3.55
Price-to-Book 1.36
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.00
Resistance 3 (R3) 15.16 14.82 14.75
Resistance 2 (R2) 14.82 14.44 14.74 14.67
Resistance 1 (R1) 14.17 14.21 14.00 14.01 14.59
Pivot Point 13.83 13.83 13.74 13.75 13.83
Support 1 (S1) 13.17 13.44 13.00 13.01 12.43
Support 2 (S2) 12.83 13.21 12.75 12.35
Support 3 (S3) 12.18 12.83 12.27
Support 4 (S4) 12.02